Search Results - "Hueman, M. T."

Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts by Hutcheson, K A, Atkins, B Z, Hueman, M T, Hopkins, M B, Glower, D D, Taylor, D A

“…Cellular cardiomyoplasty (CCM), or introduction of immature cells into terminally injured heart, can mediate repair of chronically injured myocardium. Several…”
Get full text

Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium by Atkins, B Z, Hueman, M T, Meuchel, J M, Cottman, M J, Hutcheson, K A, Taylor, D A

“…Although cardiac transplantation is an ideal treatment for end-stage heart disease, inadequate donor availability has stimulated efforts to manage terminally…”
Get more information

Cellular Cardiomyoplasty Improves Diastolic Properties of Injured Heart by Atkins, B.Zane, Hueman, Matthew T., Meuchel, Jennifer, Hutcheson, Kelley A., Glower, Donald D., Taylor, Doris A.

“…Background. Acute myocardial infarction leads to loss of functional myocytes and structural integrity that often decreases diastolic compliance and increases…”
Get full text

Comparison of immunological responses in node-positive and node-negative breast cancer patients receiving a HER2/neu E75 peptide vaccine by Hueman, M. T., Gurney, J. M., Storrer, C. E., Kotula, L., Jackson, K., Wilson, M., Shriver, C. D., Ponnian, S., Peoples, G. E.

Get full text

Using Weighted Differences in Hazards as Effect Sizes for Survival Data by Wang, H., Chen, D., Pan, Q., Hueman, M. T.

“…Sensitive to the change in sample sizes, traditional measures such as values of test statistics or p values can fail to quantify the difference in survival…”
Get full text

Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer by Woll, Michael M, Hueman, Matthew T, Ryan, Gayle B, Ioannides, Constantin G, Henderson, Charles G, Sesterhan, Isabelle A, Shrivasta, Shiv, McLeod, David G, Moul, Judd W, Peoples, George E

“…The HER2/neu protein is over-expressed in multiple epithelial tumors and the source of immunogenic peptides currently under investigation in vaccine trials in…”
Get more information

Long-term follow-up assessment of a HER-2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients by Gates, J. D., Benavides, L. C., Carmichael, M. G., Holmes, J. P., Hueman, M. T., Mittendorf, E. A., McLeod, D. G., Ponniah, S., Peoples, G. E.

“…Abstract only…”
Get full text

Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03 by Benavides, L. C., Holmes, J. P., Gates, J. D., Carmichael, M. G., Hueman, M. T., Mittendorf, E. A., von Hofe, E., Ponniah, S., Peoples, G. E.

“…Abstract only…”
Get full text

Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients by PEOPLES, George E, GURNEY, Jennifer M, HUEMAN, Matthew T, WOLL, Mike M, RYAN, Gayle B, STORRER, Catherine E, FISHER, Christine, SHRIVER, Craig D, IOANNIDES, Constantin G, PONNIAH, Sathibalan

“…E75 is an immunogenic peptide from the HER2/neu protein that is highly expressed in breast cancer. We are conducting a clinical trial of an E75 +…”
Get full text

Prognostic significance of HLA-A2 status in breast cancer patients by Dehqanzada, Z., Hueman, M. T., Shriver, C. D., Ponniah, S., Peoples, G. E.

“…Abstract only…”
Get full text

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients by Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., Shriver, C. D., Ioannides, C. G., Ponniah, S., Peoples, G. E.

“…Abstract only…”
Get full text

Abstract P4-06-09: HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions by Chen, Y, Kovatich, AJ, Fantacone-Campbell, JL, Hooke, JA, Kvecher, L, Kovatich, AW, Gallagher, CM, Hueman, MT, Hyslop, T, Mural, RJ, Shriver, CD, Rui, H, Hu, H

“…Abstract Background There are multiple subtypes in invasive breast cancers (IBCs). Immunohistochemistry (IHC)-based assays using ER, PR, HER2, and Ki67 for…”
Get full text

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex registered technology by Dehqanzada, Z A, Storrer, CE, Hueman, M T, Foley, R J, Harris, KA, Jama, Y H, Shriver, C D, Ponniah, S, Peoples, GE

“…We used the Luminex assay to compare serum cytokine profiles of breast cancer patients (BCa) to healthy controls, node-positive (NP) patients to node-negative…”
Get full text

Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity wounds by Lisboa, Felipe A., MD, Bradley, Matthew J., MD, Hueman, Matthew T., MD, Schobel, Seth A., PhD, Gaucher, Beverly J., PhD, Styrmisdottir, Edda L., MSc, Potter, Benjamin K., MD, Forsberg, Jonathan A., MD, PhD, Elster, Eric A., MD

“…Background After adequate operative debridement and antimicrobial therapies, combat-related extremity wounds that either heal or fail are both associated with…”
Get full text

Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients by HUEMAN, Matthew T, DEHQANZADA, Zia A, PONNIAH, Sathibalan, PEOPLES, George E, NOVAK, Thomas E, GURNEY, Jennifer M, WOLL, Michael M, RYAN, Gayle B, STORRER, Catherine E, FISHER, Christine, MCLEOD, David G, IOANNIDES, Constantine G

“…Purpose: The E75 peptide is an immunogenic peptide from the HER-2/ neu protein that is substantially expressed in prostate cancer. We are conducting a clinical…”
Get full text

Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients by DEHQANZADA, Zia A, STORRER, Catherine E, HUEMAN, Matthew T, FOLEY, Rebecca J, HARRIS, Katie A, JAMA, Yusuf H, KAO, Tzu-Cheg, SHRIVER, Craig D, PONNIAH, Sathibalan, PEOPLES, George E

“…Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic variables and…”
Get full text

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/ neu peptide (AE37) by Gates, JD, Benavides, LC, Carmichael, MG, Hueman, MT, Holmes, JP, Khoo, S, Stojadinovic, A, von Hofe, E, Ponniah, S, Peoples, GE

“…Abstract Abstract #3134 Background: CD4+CD25+FOXP3+ regulatory T cells (Tregs) have been implicated in the suppression of immune responses against various…”
Get full text

Management of Gastrointestinal Stromal Tumors by Hueman, Matthew T., MD, Schulick, Richard D., MD

“…A gastrointestinal stromal tumor (GIST) is a rare mesenchymal malignancy of the gastrointestinal (GI) tract. Malignant GISTs were first defined as a separate…”
Get full text

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial by Patil, Ritesh, MD, Clifton, Guy T., MD, Holmes, Jarrod P., MD, Amin, Asna, MD, Carmichael, Mark G., MD, Gates, Jeremy D., MD, Benavides, Linda H., MD, Hueman, Matthew T., MD, Ponniah, Sathibalan, PhD, Peoples, George E., MD, FACS

“…Background We have treated disease-free breast cancer patients with an HER2/ neu -derived peptide, E75, as an adjuvant vaccine. E75 was originally described as…”
Get full text

Management of Retroperitoneal Sarcomas by Hueman, Matthew T., MD, Herman, Joseph M., MD, MSc, Ahuja, Nita, MD

“…Retroperitoneal sarcomas present a therapeutic challenge based on their location, extent of invasion at diagnosis, and propensity for local recurrence…”
Get full text